Lithium Australia (ASX:LIT)
No one expected lithium batteries, energy storage and electric cars to put their stamp on global markets quite as quickly and efficiently as has occurred. The good news is lithium is still at the incubation stage with many ambitious lithium explorers remaining undervalued.
One potentially undervalued lithium stock is the A$39.5 million capped Lithium Australia (ASX:LIT).
LIT is making all the right noises and taking the necessary steps to achieve its underlying goal: to become the preeminent hub for lithium exploration, extraction, and processing.
Over the past 12 months, LIT has been working diligently to commercialise its 100%-owned SiLeach® lithium extraction technology.
LIT’s blue-sky potential is rooted in the fact that this still-small ASX lithium developer, could have the keys to unlocking high-grade lithium for any manufacturer, or end-user, at a fraction of the current cost .
In addition to its technology, LIT aims to produce lithium at a discount to traditionally cheaper brine producers. That’s never been done before… and if it comes off as LIT hopes it will, it will be a major disruptive factor for the lithium industry.
The information on this page should not be the only trigger for your investment decision. Click on the links below for a more in-depth and informed examination of the company. We strongly recommend you seek professional financial advice whenever making financial investment decisions.
LIT is stone-cold serious about turning geological curiosities into defined ore bodies, without putting all its eggs into extensive exploration. This technology and peripheral exploration combo-strategy, is poised to reel in the spoils as the commercial tide of the lithium industry continues to rise.
LIT Closing the Loop on Energy Metals with Peerless Innovation
Jul 26, 2018
Lithium Australia NL (ASX:LIT) continues to make progress in its bid to ‘close the loop’ on the energy metal cycle.
Related Lithium Australia (ASX:LIT) articles
ASX Junior’s Under-Drilled Cuban Oil Asset Puts it in Multi-Billion Barrel Company
Nov 15, 2018
Zero Safety Issues for IMU’s Immunotherapy Cancer Treatment: Phase II Trial Imminent
Nov 13, 2018